Who
Jill Carroll
Director
Company insider
Files Form 4 as: Director, Avalyn Pharma; Director, Arcellx; Director and 10% owner, Pandion Therapeutics; Director and 10% owner, Applied Genetic Technologies.
In numbers
- Trades disclosed
- 49
- Buys
- 4
- Sells
- 5
- Bought
- $42.7M
- Sold
- $103.3M
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 1 Apr 2014
- Last trade
- 1 May 2026
- Last filed
- 1 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 May 2026filed 1 May 2026 | AVLN Avalyn PharmaBiotechnology | SEC FORM 4 Code C | —1,419,298 | filing |
| 1 May 2026filed 1 May 2026 | AVLN Avalyn PharmaBiotechnology | SEC FORM 4 Code C | —489,486 | filing |
| 1 May 2026filed 1 May 2026 | AVLN Avalyn PharmaBiotechnology | SEC FORM 4 Bought | $5.0M277,778 at $18.00 | filing |
| 1 May 2026filed 1 May 2026 | AVLN Avalyn Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code C | —27,309,719 | filing |
| 1 May 2026filed 1 May 2026 | AVLN Avalyn Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code C | —9,418,561 | filing |
| 1 May 2026filed 1 May 2026 | AVLN Avalyn Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code C | —27,309,719 | filing |
| 1 May 2026filed 1 May 2026 | AVLN Avalyn Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code C | —9,418,561 | filing |
| 1 May 2026filed 1 May 2026 | AVLN Avalyn PharmaBiotechnology | SEC FORM 4 Code C | —1,419,298 | filing |
| 1 May 2026filed 1 May 2026 | AVLN Avalyn PharmaBiotechnology | SEC FORM 4 Code C | —489,486 | filing |
| 1 May 2026filed 1 May 2026 | AVLN Avalyn PharmaBiotechnology | SEC FORM 4 Bought | $5.0M277,778 at $18.00 | filing |
| 28 Apr 2026filed 28 Apr 2026 | ArcellxBiotechnology | SEC FORM 4 Code U | —1,479,148 | filing |
| 28 Apr 2026filed 28 Apr 2026 | Arcellxoption or derivative · Biotechnology | SEC FORM 4 Code D | —11,459 | filing |
| 28 Apr 2026filed 28 Apr 2026 | Arcellxoption or derivative · Biotechnology | SEC FORM 4 Code D | —8,011 | filing |
| 28 Apr 2026filed 28 Apr 2026 | Arcellxoption or derivative | SEC FORM 4 Code D | —11,459 | filing |
| 28 Apr 2026filed 28 Apr 2026 | Arcellxoption or derivative | SEC FORM 4 Code D | —8,011 | filing |
| 28 Apr 2026filed 28 Apr 2026 | Arcellxoption or derivative | SEC FORM 4 Code D | —9,174 | filing |
| 28 Apr 2026filed 28 Apr 2026 | Arcellxoption or derivative · Biotechnology | SEC FORM 4 Code D | —9,174 | filing |
| 28 Apr 2026filed 28 Apr 2026 | Arcellx | SEC FORM 4 Code U | —1,479,148 | filing |
| 29 May 2025filed 30 May 2025 | Arcellxoption or derivative | SEC FORM 4 Code A | —9,174 at $0.00 | filing |
| 28 May 2024filed 6 Jun 2024 | Arcellxoption or derivative | SEC FORM 4 Code A | —8,011 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.